Physician profile
Kala Hurst
NPI 1700522992
$2,330.40
in general payments reported to CMS, 2019-2025
15 companies · $992 in 2025
The $992 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $307 · 2023: $562 · 2024: $469 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.44 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $424.18 | 2023-2025 | Bimzelx, Cimzia |
| Organon LLC | $287.47 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $240.35 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $181.21 | 2023-2025 | Spevigo |
| Amgen INC. | $179.05 | 2023-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $173.56 | 2025 | |
| Abbvie INC. | $169.34 | 2023-2025 | |
| Genzyme Corporation | $158.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $152.36 | 2023-2024 | Libtayo, Dupixent |
| Novo Nordisk INC | $97.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $86.48 | 2022 | |
| Lilly USA, LLC | $80.72 | 2024 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2023 | |
| Helsinn Therapeutics (U.S.), INC. | $22.99 | 2025 | Valchlor |
| Incyte Corporation | $16.76 | 2024 | Opzelura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kala Hurst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.